A recently completed survey of 63 manufacturers of diphtheria-tetanus-
pertussis (DTP) vaccine and its components in 42 countries shows that
there is potentially a large excess installed capacity for DTP product
ion. However, many manufacturers ave not producing to capacity, and de
mand and supply for this vaccine are not matched in individual countri
es, About half of all countries producing DTP vaccine and its componen
ts do not have fully functional national control systems, and some cou
ntries are performing none of the critical functions for an effective
control of quality. Thus, potential for export of excess capacity is l
imited. The data collected indicate much homogeneity in the preparatio
n of diphtheria and tetanus toxoids. Nearly all manufacturers use the
same seeds and similar purification methods, but there is variability
in whether purification is done before or after conversion of toxin to
toroid, About 10% of all manufacturers do not meet WHO-defined standa
rds of purity for these toroids. There is much move heterogeneity in t
he pertussis seed strains and the methods of purification used. The fo
rmulation of DTP vaccine differs considerably among producers. Potency
testing is not being done by the WHO-recommended method by about 50%
of manufacturers on lots of diphtheria and tetanus toxoids for release
. Testing of irreversibility of conversion of toxin to toroid, a WHO-s
pecified safety test, is also not being clone on each lot of diphtheri
a toroid by 15% of manufacturers surveyed nor on each lot of tetanus t
oroid vaccine by 30% of manufacturers surveyed. Access to technology t
o develop new DTP-based combination vaccines will be delayed if these
manufacturers cannot ensure consistent high quality vaccine for their
target populations. The results and conclusions suggest areas for futu
re activities to strengthen the supply and quality of DTP and DTP-base
d combination vaccines. Copyright (C) 1996 Elsevier Science Ltd.